Xeris Biopharma Holdings Inc.
Organization details
- Legal name
- Xeris Biopharma Holdings Inc.
- Ownership
- Public
- Status
- Active
- Sector (GICS)
- Health Care
- SIC code
- 2834 — Pharmaceutical Preparations
- Headquarters city
- Chicago
- Headquarters state / province
- Illinois
- Headquarters country
- United States
- Fiscal year end
- December
- Ticker symbol
- XERS
- Primary stock exchange
- Nasdaq
Identifiers
- SEC CIK
- 0001867096
- EIN
- 87-1082097
Board of directors
-
Barbara-Jean Anne Bormann-Kennedy · DirectorSince 2023
-
Dawn Halkuff · DirectorSince 2023
-
Garheng Kong · DirectorSince 2023
-
James Aloysius Brady · DirectorSince 2025
-
Jeffrey W. Sherman · DirectorSince 2023
-
John Johnson · DirectorSince 2023
- Since 2023
-
John Patrick Shannon Jr. · Director · See RemarksSince 2024
-
Marla Persky · DirectorSince 2023
-
Menassie Taddese · DirectorSince 2026
-
Nerissa Kreher · DirectorSince 2026
-
Paul R. Edick · Director · See RemarksSince 2023
-
Ricki Louise Fairley · DirectorSince 2023
Director election results
Annual meeting of June 4, 2026. Support is votes for as a share of votes for and against (or withheld). Below 80% is a clear protest.
-
60.2%
-
71.5%
Board connections
7 of this board's directors also sit on 13 other boards. 12 are in the same sector.
-
AnaptysBio Inc. Same sectorvia John P. Schmid
-
Axogen Inc. Same sectorvia John Johnson
-
BioLineRx Ltd. Same sectorvia Barbara-Jean Anne Bormann-Kennedy
-
BlossomHill Therapeutics Inc. Same sectorvia John P. Schmid
-
BridgeBio Oncology Therapeutics Inc. Same sectorvia John P. Schmid
-
Design Therapeutics Inc. Same sectorvia John P. Schmid
-
First Tracks Biotherapeutics Inc. Same sectorvia John P. Schmid
- via John P. Schmid
-
Labcorp Holdings Inc. Same sectorvia Garheng Kong
-
Larimar Therapeutics Inc. Same sectorvia Jeffrey W. Sherman
-
Rezolute Inc. Same sectorvia Nerissa Kreher
-
Verastem Inc. Same sectorvia John Johnson
-
Vistagen Therapeutics Inc. Same sectorvia Paul R. Edick
Insider trades
All notable trades →From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.
- Bought, last 12 months
- $0
- 0 purchases by 0 insiders
- Sold, last 12 months
- $5,830,808
- 35 sales by 9 insiders
| Date | Insider | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|
| Nov 5, 2026 | McCulloch Kevin Officer (See Remarks) | Open-market sale | −25,000 | $12.49 | $312,215 |
| Nov 2, 2026 | Hecht Beth Officer (See Remarks) | Open-market sale | −25,000 | $10.23 | $255,828 |
| Nov 2, 2026 | McCulloch Kevin Officer (See Remarks) | Open-market sale | −15,000 | $10.23 | $153,488 |
| Nov 2, 2026 | Pieper Steven Officer (See Remarks) | Open-market sale | −5,000 | $10.23 | $51,174 |
| Nov 2, 2026 | Menassie Taddese Director | Grant or award | +22,365 | — | — |
| Oct 1, 2026 | Hecht Beth Officer (See Remarks) | Open-market sale | −16,666 | $9.41 | $156,792 |
| Oct 1, 2026 | McCulloch Kevin Officer (See Remarks) | Open-market sale | −15,000 | $9.41 | $141,120 |
| Oct 1, 2026 | Pieper Steven Officer (See Remarks) | Open-market sale | −5,000 | $9.41 | $47,037 |
| Sep 28, 2026 | McCulloch Kevin Officer (See Remarks) | Open-market sale | −25,000 | $10.00 | $250,000 |
| Sep 1, 2026 | Hecht Beth Officer (See Remarks) | Open-market sale | −16,666 | $8.49 | $141,494 |
| Sep 1, 2026 | McCulloch Kevin Officer (See Remarks) | Open-market sale | −15,000 | $8.49 | $127,350 |
| Sep 1, 2026 | Pieper Steven Officer (See Remarks) | Open-market sale | −5,000 | $8.50 | $42,500 |
| Aug 12, 2026 | Pieper Steven Officer (See Remarks) | Open-market sale | −5,000 | $8.50 | $42,500 |
| Aug 3, 2026 | Hecht Beth Officer (See Remarks) | Open-market sale | −16,666 | $8.01 | $133,495 |
| Aug 3, 2026 | McCulloch Kevin Officer (See Remarks) | Open-market sale | −15,000 | $8.02 | $120,300 |
Peers
Compare boardsOrganizations in the same sector, closest in location and size first.
Questions about Xeris Biopharma Holdings Inc.
How many directors are on Xeris Biopharma Holdings Inc.'s board?
Xeris Biopharma Holdings Inc.'s board has 13 directors: Barbara-Jean Anne Bormann-Kennedy, Dawn Halkuff, Garheng Kong, James Aloysius Brady, Jeffrey W. Sherman, John Johnson, John P. Schmid, John Patrick Shannon Jr., Marla Persky, Menassie Taddese and 3 others.
Are Xeris Biopharma Holdings Inc. insiders buying or selling shares?
Over the last 12 months, Xeris Biopharma Holdings Inc. insiders made no open-market purchases and sold $5.8 million of shares in 35 sales on the open market, as reported to the SEC on Forms 4 and 5.
Embed this board on your site
Paste this where the board should appear. It always shows the current directors and links back here.
<div data-bod-board="xeris-biopharma-holdings-inc"></div>
<script src="https://boardofdirectors.review/embed.js" async></script>
Reviews (0)
Sign in to write a review.
No reviews yet. Be the first to write one.